PRODUCT TYPES – Page 26

Biologic comparability failure after process change after filling line intervention: how to justify rework/reprocessing vs rejection for biologic lots

Identifying symptoms and signals is the first step in investigating biologic comparability failures. These indicators can manifest in several forms:Click to read the full article.

Supply interruption risk during lifecycle management: CAPA with limited data sets

The first step in identifying a supply interruption risk is to recognize the signals on the manufacturing floor or in the laboratory. Symptoms may manifest as:Click to read the full…

Biologic viral clearance validation gap after equipment qualification update: patient safety impact assessment and batch disposition governance

The initial detection of a biologic viral clearance validation gap often emerges through various symptoms reported either on the manufacturing floor or within laboratory environments. Common signals include:Click to read…

Method variability OOS during inspection readiness: FDA/EMA communication strategy

Identifying signals that indicate potential method variability OOS is critical for timely intervention. Symptoms frequently arise during routine testing or quality control (QC) assessments. Common signs include:Click to read the…

Biologic container closure integrity failure during CPV trending review: patient safety impact assessment and batch disposition governance

Spotting the early signs of container closure integrity failures is crucial. Symptoms can occur at various stages throughout the manufacturing process. Here are some common signals:Click to read the full…

Supply interruption risk during regulatory review: FDA/EMA communication strategy

Identifying early warning signs of potential supply interruptions is pivotal. Symptoms can emerge from various sources within the manufacturing process, from production lines to laboratory settings. Experienced professionals must be…

Biosimilar aggregate level increase after cell line or upstream change: CAPA strategy to restore similarity and prevent regulatory delays

Recognizing symptoms that indicate a rise in aggregate levels is critical to the timely identification of underlying issues. Some potential signals to look out for include:Click to read the full…

Specification justification gap during regulatory review: FDA/EMA communication strategy

Addressing Specification Justification Gaps During Regulatory Review: A Comprehensive Investigation Approach In the pharmaceutical industry, gaps in specification justification can create significant roadblocks during regulatory reviews by bodies such as…

Biosimilar comparability package deficiency during biosimilar development: risk assessment for critical quality attributes and clinical impact

Detecting symptoms of a biosimilar comparability package deficiency begins in the lab or during production. These symptoms can manifest as:Click to read the full article.

Supply interruption risk during inspection readiness: risk-based GMP justification

Recognizing the symptoms of supply interruption risk at an early stage is essential to avoid major disruptions in production. Symptoms may manifest in numerous ways, including:Click to read the full…

Biosimilar method transfer failure across labs during stability pull comparisons: FDA/EMA expectations for root cause, rework, and comparability justification

Recognizing early signals of method transfer failure is critical. Symptoms may emerge through various channels, recommending immediate attention to the process. Here are typical indicators observed on the manufacturing floor…

Supply interruption risk during small-batch manufacturing: FDA/EMA communication strategy

Identifying early warning signs of supply interruption risks is crucial in mitigating their impact. Symptoms can manifest within different operational contexts, including raw material handling, equipment operation, and quality testing.…